18 completed, 2 withdrawn. 20 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 20 | Completed 18, Withdrawn 2 |
| Phase 1 | 5 | Completed 5 |
Follow Recurrent Squamous Cell Carcinoma of the Hypopharynx: new trials by email Literature Review of Recurrent Squamous Cell Carcinoma of the Hypopharynx trials Research Report on Recurrent Squamous Cell Carcinoma of the Hypopharynx
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy placebo, quality-of-life assessment, questionnaire administration - Mucositis, Recurrent Squamous Cell Carcinoma of the Hypopharynx | Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2013-05-01 | 2013-05-15 | |
| PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer PI3K inhibitor BKM120, cetuximab - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 1 / Phase 2 | Completed | University of Chicago | 12 | 2013-05-01 | 2021-10-05 |
| Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer cetuximab, paclitaxel, carboplatin - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 2 | Completed | Fox Chase Cancer Center | 24 | 2011-02-16 | 2018-02-26 |
| Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck lapatinib ditosylate, capecitabine - Head and Neck Cancer, Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma | Phase 2 | Completed | Abramson Cancer Center at Penn Medicine | 44 | 2009-10-01 | 2020-03-19 |
| Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab cetuximab, placebo, sorafenib tosylate - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 2 | Completed | National Cancer Institute (NCI) | 55 | 2009-07-01 | 2026-03-10 |
| Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer saracatinib, laboratory biomarker analysis - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 2 | Completed | National Cancer Institute (NCI) | 9 | 2007-07-01 | 2014-04-30 |
| Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer dasatinib, pharmacological study, laboratory biomarker analysis - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 2 | Completed | National Cancer Institute (NCI) | 15 | 2007-07-01 | 2014-10-01 |
| Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer bevacizumab, placebo, magnetic resonance imaging - Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma | Phase 2 | Completed | National Cancer Institute (NCI) | 11 | 2007-06-01 | 2014-05-09 |
| Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer sunitinib malate - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 2 | Completed | National Cancer Institute (NCI) | 22 | 2006-08-01 | 2014-07-25 |
| Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck bortezomib, irinotecan hydrochloride, laboratory biomarker analysis - Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx | Phase 2 | Completed | National Cancer Institute (NCI) | 71 | 2005-07-01 | 2014-05-23 |
| Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer lapatinib ditosylate, laboratory biomarker analysis - Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx | Phase 2 | Completed | National Cancer Institute (NCI) | 30 | 2005-03-01 | 2015-04-15 |
| Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer erlotinib hydrochloride, cetuximab, bevacizumab - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 66 | 2005-01-01 | 2014-06-11 |
| SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer ispinesib, laboratory biomarker analysis, pharmacological study - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 2 | Completed | National Cancer Institute (NCI) | 21 | 2005-01-01 | 2017-03-06 |
| Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer lapatinib ditosylate, laboratory biomarker analysis - Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 2 | Completed | National Cancer Institute (NCI) | 88 | 2004-10-01 | 2014-01-07 |
| S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer sorafenib tosylate, laboratory biomarker analysis - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 2 | Completed | National Cancer Institute (NCI) | 40 | 2004-10-01 | 2013-02-28 |
| Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck erlotinib hydrochloride, pharmacological study, pharmacogenomic studies - Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 80 | 2003-04-01 | 2013-01-09 |
| Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer bevacizumab, erlotinib hydrochloride, laboratory biomarker analysis - Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 58 | 2003-03-01 | 2018-10-02 |
| Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck ixabepilone, laboratory biomarker analysis - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 2 | Completed | National Cancer Institute (NCI) | 144 | 2002-11-01 | 2013-02-27 |
| Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer erlotinib hydrochloride, docetaxel, laboratory biomarker analysis - Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 45 | 2002-10-01 | 2013-11-25 |
| S0225 Capecitabine in Treating Patients Who Have Undergone Surgery for Locally Recurrent or Persistent Head and Neck Cancer capecitabine, adjuvant therapy, chemotherapy - Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity | Phase 2 | Withdrawn | SWOG Cancer Research Network | 2013-11-08 |
Squamous Cell Carcinoma of Head and Neck (20) · Salivary Gland Neoplasms (12) · Tongue Neoplasms (10) · Carcinoma, Non-Small-Cell Lung (2) · Esthesioneuroblastoma, Olfactory (2) · Astrocytoma (1) · Brain Neoplasms (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Renal Cell (1) · Choroid Plexus Neoplasms (1) · Colonic Neoplasms (1) · Ependymoma (1) · Glioma (1) · Head and Neck Neoplasms (1) · Hemangiopericytoma, Malignant (1)
Carcinoma (20) · Carcinoma, Squamous Cell (20) · Neoplasms by Histologic Type (20) · Neoplasms by Site (20) · Neoplasms, Glandular and Epithelial (20) · Head and Neck Neoplasms (19) · Neoplasms (19) · Mouth Diseases (15) · Mouth Neoplasms (15) · Stomatognathic Diseases (15) · Salivary Gland Diseases (12) · Tongue Diseases (10) · Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Cranial Nerve Diseases (2)
Erlotinib Hydrochloride (5) · Cetuximab (4) · Bevacizumab (3) · Lapatinib (3) · Capecitabine (2) · N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine (2) · Sorafenib (2) · Bortezomib (1) · CK0238273 (1) · Carboplatin (1) · Chemotherapy, Adjuvant (1) · Dasatinib (1) · Docetaxel (1) · Drug Therapy (1) · Irinotecan (1)
National Cancer Institute (NCI) (15) · Abramson Cancer Center at Penn Medicine (1) · Fox Chase Cancer Center (1) · Roswell Park Cancer Institute (1) · SWOG Cancer Research Network (1) · University of Chicago (1)
United States (17) · Canada (1)
Ezra Cohen (2) · Jill Gilbert (2) · Tanguy Seiwert (2) · Alain Mita (1) · Anurag Singh (1) · Barbara Burtness (1) · Charles Rudin (1) · Christopher Thomas (1) · Corey Langer (1) · David Schwartz, MD (1) · Eric Kraut (1) · Eric Winquist (1) · Jessica Bauman, MD (1) · Matthew Fury (1) · Monica Loghin (1)
PMID 19201650, PMID 25057165, PMID 40166973
N01CM62201 (3), N01CM62202 (2), P30CA014599 (2), P30CA016672 (2), U10CA021115 (2), U10CA032102 (2), N01CM00100 (1), N01CM62203 (1), N01CM62206 (1), N01CM62209 (1), P30CA006927 (1), P30CA054174 (1), P30CA076292 (1), U01CA069852 (1), U01CA069853 (1)